Sue Gibbs

Sue Gibbs

Sue Gibbs

Biography 

Prof. Dr Sue Gibbs studied human biochemistry and physiology at Sheffield University, England and went on to obtain her PhD in 1991 at the Department of Molecular Genetics, Leiden University. Her entire career has focused on human skin and oral mucosa biology, and in particular in animal alternative methods to develop novel therapeutic strategies for treating and preventing human disease. As a Postdoc in LUmc (1993), the development of ‘in vivo like’ human skin and oral mucosa equivalents were her major interest. Sue Gibbs became head of the Dermatology Laboratory, VUmc in 2001. This position opened the opportunity to expand the research on tissue engineered skin for human clinical wound healing and in vitro alternatives for animal tests. In 2005, she participated and co-managed the European Sixth Framework project “Sens-it-iv” which focused on novel testing strategies for in vitro assessment of allergens.  In 2006, Sue Gibbs co-founded and became Chief Scientific Officer of the VU University Medical Centre spin-off company A-Skin Nederland B.V. in order to develop the clinical and in vitro assay potential of her animal alternative technologies. In July 2012, Prof Gibbs’ leading position in the field of skin tissue engineering was be awarded with the Fenna Diemer-Lindeboom chair as Professor of Skin and Mucosa Regenerative Medicine aimed at promoting female scientific talent.  This unique position is jointly supported by the VU University Medical Centre and the Academic Centre for Dentistry Amsterdam (ACTA). Current focus lies with developing immune competent skin and oral mucosa tissue engineered constructs to understand the physiology of chronic wounds and adverse scar formation (keloids, hypertrophic scars) and to understand similarities and differences between allergic and irritant contact dermatitis with the aim of identifying novel drug targets and personalized as well as general therapeutic strategies. Recently, her research has extended into the field of hair follicles and importantly “organ-on-a-chip’’, in particular immune competent “skin-on-a-chip’’, which has the potential to provide a personalized medicine approach to treating cancer. In 2015, Sue Gibbs received the national Lef in the Lab’’ prize by the Dutch Animal Protection society for her immune competent skin-on-chip project.

Education:

Ph.D. Leiden University, 1991

Representative Publications:

– MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. Kosten IJ,  Gibbs S. Toxicol Appl Pharmacol. 2015; 15;287(1):35-42.

– Development, Validation, and Testing of a Human Tissue Engineered Hypertrophic Scar Model. van den Broek LJ, Gibbs S. ALTEX. 2012; 29(4):389-402.
– Long-Term Expansion in Platelet Lysate Increases Growth of Peripheral Blood-Derived Endothelial-Colony Forming Cells and Their Growth Factor-Induced Sprouting Capacity. L Tasev D, …., Gibbs S,  Koolwijk P. PLoSOne. 2015 Jun 15;10(6):e0129935.chip

– Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. Wijnker PJM,…., Gibbs S, van der Velden J, Carrier L. Journal of Molecular and Cellular Cardiology 2016; 97:82-92.

VUmc

VUmc

This is a unique website which will require a more modern browser to work! Please upgrade today!

Social Media Auto Publish Powered By : XYZScripts.com